Berkshire Asset Management’s ImmunityBio IBRX Stock Holding History

Berkshire Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,000	Closed	-$84K	–	230
2022 Q1	$84K	Hold	15,000	–	–	0.01%	200
2021 Q4	$91K	Sell	15,000 -5,000	-25%	-$37.6K	0.01%	237
2021 Q3	$195K	Hold	20,000	–	–	0.01%	233
2021 Q2	$286K	Buy	20,000 +5,000	+33%	+$82.6K	0.02%	200
2021 Q1	$356K	Hold	15,000	–	–	0.03%	173
2020 Q4	$200K	Buy	+15,000	New	+$144K	0.02%	213

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Berkshire Asset Management's IBRX Position: Q2 2022 in Review

Berkshire Asset Management sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 15,000 shares — an estimated $84K sold.

Berkshire Asset Management first reported a position in IBRX in Q4 2020 and held it in 6 quarters. The position peaked at $356K in Q1 2021. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

Berkshire Asset Management reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
Berkshire Asset Management sold 15,000 ImmunityBio shares in Q2 2022, an estimated $84K.
Berkshire Asset Management first reported a position in ImmunityBio in Q4 2020 and held it in 6 quarters.
Berkshire Asset Management's ImmunityBio position peaked at $356K in Q1 2021.
131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Berkshire Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.